| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32ba6a90136d9d2e6f9285178e95bf78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e61263b84630539d1fc5281e3bd9ac4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_243c3f54735608c90a5be39b4241ab90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cfa4cb326178d0e4ec276ea25af576f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e21899ab9ebf67bb206679e57a6ee80f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b18e2d1b7ffcf52cbf5c01f9287574b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6184a5846496e3fae4c5ba86cddc4cd5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate |
2003-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_faca621f082104dc85315547769f12dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eeaa1b120353fe22d31362c6ed899f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2aee524d11fdf29949f0d50725b7a89b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0aeb297089ed780e326de1ba61de1f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5557864dd92ba9afd5a76987e0df55af |
| publicationDate |
2003-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03082858-A1 |
| titleOfInvention |
Crystalline forms of rabeprazole sodium |
| abstract |
The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium. Achiphex7 (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. The chemical designation of Rabeprazole sodium is 2-[[[4-(3-methoxypropoxy)-3 methyl-2-pyridinyl]-methyl] sulfinyl]-1H-benzimidazole sodium. It may be represented by Formula (1). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010006904-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-019543-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006120701-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8071781-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4884967-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1935891-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1674463-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1452533-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010006904-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8143409-B2 |
| priorityDate |
2002-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |